Roche Considers Pricing Flexibility For Avastin In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Similar to Genentech’s price cap on Avastin in the U.S., Roche is evaluating “creative” pricing approaches following breast cancer approval.